Pancreatic Cancer Trial Results
- Combination of Nab-Paclitaxel and Gemcitabine Improves Survival in Patients with Metastatic Pancreatic Cancer
(Posted: 11/15/2013) - In an international randomized phase III trial, patients with metastatic pancreatic cancer who were treated with a combination of albumin-bound paclitaxel (nab-paclitaxel [Abraxane®]) and gemcitabine (Gemzar®) lived longer than patients who were treated with gemcitabine alone. Patients who received both drugs also lived longer without their disease getting worse (progression-free survival).
- Chemotherapy Regimen Extends Survival in Advanced Pancreatic Cancer Patients
(Posted: 06/07/2011) - A four-drug chemotherapy regimen has produced the longest improvement in survival ever seen in a phase III clinical trial of patients with metastatic pancreatic cancer, one of the deadliest types of cancer.
- Targeted Therapies May Be Effective Against Rare Pancreatic Cancer
(Posted: 04/08/2011) - In two phase III clinical trials published February 9, 2011, in the New England Journal of Medicine (NEJM), the targeted therapies sunitinib and everolimus improved outcomes for patients with pancreatic neuroendocrine tumors.
- Can Aspirin Reduce Cancer Risk and Mortality?
(Posted: 03/30/2011) - A meta-analysis of eight clinical trials involving regular aspirin use showed a substantial reduction in mortality for a number of different cancers.